Your Article Summary
See Latest ArticlesPostmenopausal hormone therapy and the risk of cardiovascular disease
Expert Opinion in Pharmacotherapy, 07/01/09
Bittner V - Risks of hormone therapy seem to predominate among older postmenopausal women. Data among younger women close to menopause are insufficient to recommend such therapy for cardiovascular disease prevention.
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Polypill: the evidence and the promise
Current Opinion in Lipidology, 12/15/09
Combination therapy of statins and fibrates in the management of cardiovascular risk
Current Opinion in Lipidology, 12/15/09
Personalized antiplatelet therapy for coronary artery disease patients: is this the future?
Expert Review of Cardiovascular Therapy , 12/15/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability
Journal of Pharmacy and Pharmacology, 12/15/09
Novel TNF antagonists for the treatment of rheumatoid arthritis
Expert Opinion on Investigational Drugs, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09